BCPC - Balchem Corp Stock Price, Fair Value and News

140.64USD-4.43 (-3.05%)Market Closed

Market Summary

USD140.64-4.43

Market Closed

-3.05%

BCPC Stock Price

View Fullscreen

BCPC RSI Chart

BCPC Valuation

Market Cap

4.7B

Price/Earnings (Trailing)

43.13

Price/Sales (Trailing)

5.07

EV/EBITDA

27.22

Price/Free Cashflow

25.47

BCPC Price/Sales (Trailing)

BCPC Profitability

Operating Margin

32.75%

EBT Margin

14.88%

Return on Equity

10.3%

Return on Assets

6.8%

Free Cashflow Yield

3.93%

BCPC Fundamentals

BCPC Revenue

Revenue (TTM)

922.4M

Rev. Growth (Yr)

-1.65%

Rev. Growth (Qtr)

-0.54%

BCPC Earnings

Earnings (TTM)

108.5M

Earnings Growth (Yr)

24.49%

Earnings Growth (Qtr)

-8.35%

Breaking Down BCPC Revenue

Last 7 days

-0.4%

Last 30 days

-6.8%

Last 90 days

3.8%

Trailing 12 Months

12.5%

How does BCPC drawdown profile look like?

BCPC Financial Health

Current Ratio

2.12

Debt/Equity

0.15

Debt/Cashflow

1.01

BCPC Investor Care

Shares Dilution (1Y)

0.30%

Diluted EPS (TTM)

3.35

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	946.0M	940.6M	926.3M	922.4M
2022	842.2M	876.6M	923.0M	942.4M
2021	714.9M	743.9M	766.6M	799.0M
2020	661.1M	672.9M	689.5M	703.6M
2019	639.3M	637.2M	640.7M	643.7M
2018	618.5M	635.1M	639.4M	643.7M
2017	555.8M	564.1M	576.3M	594.8M
2016	542.8M	546.8M	545.2M	553.2M
2015	600.3M	602.8M	582.4M	552.5M
2014	338.5M	387.5M	460.3M	541.4M
2013	318.8M	323.1M	335.6M	337.2M
2012	295.1M	299.4M	300.1M	310.4M
2011	268.2M	281.4M	291.9M	291.9M
2010	228.3M	237.3M	246.2M	255.1M
2009	0	0	0	219.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Balchem Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 08, 2024	tignor michael brent	acquired	358,680	85.4	4,200	svp & chief hr officer
Mar 08, 2024	tignor michael brent	sold	-840,985	157	-5,339	svp & chief hr officer
Mar 04, 2024	wineinger matthew david	sold	-209,128	156	-1,333	-
Feb 26, 2024	backus william a.	sold	-1,086,300	155	-7,000	vp & chief accounting officer
Feb 23, 2024	backus william a.	sold	-1,435,470	156	-9,180	vp & chief accounting officer
Feb 23, 2024	backus william a.	acquired	738,421	80.438	9,180	vp & chief accounting officer
Feb 22, 2024	harris theodore l	sold	-5,300,030	154	-34,350	chairman, president & ceo
Feb 22, 2024	harris theodore l	acquired	2,030,400	59.1091	34,350	chairman, president & ceo
Feb 21, 2024	harris theodore l	sold	-4,558,030	153	-29,679	chairman, president & ceo
Feb 21, 2024	sestrick michael robert	acquired	871,999	78.5585	11,100	svp & chief technology officer

Which funds bought or sold BCPC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	FIFTH THIRD BANCORP	added	2.59	19,732	307,266	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	303	2,649	-%
Apr 23, 2024	KLR INVESTMENT ADVISORS, LLC	reduced	-6.62	-38,230	334,724	0.24%
Apr 23, 2024	LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA	unchanged	-	10,787	435,472	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-25.71	-462,000	1,582,000	0.01%
Apr 23, 2024	Louisiana State Employees Retirement System	reduced	-0.62	84,325	2,479,200	0.05%
Apr 22, 2024	WENDELL DAVID ASSOCIATES INC	unchanged	-	133,000	3,328,000	0.34%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	414,535	2,495,430	0.02%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	24.5	1,753,000	7,657,770	-%
Apr 22, 2024	PFG Investments, LLC	new	-	464,850	464,850	0.03%

Are Funds Buying or Selling BCPC?

Are funds buying BCPC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BCPC

No. of Funds

Unveiling Balchem Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	11.76%	3,791,512	SC 13G/A
Feb 09, 2024	wasatch advisors lp	-	0	SC 13G/A
Feb 07, 2024	apg asset management us inc.	9.0%	2,917,112	SC 13G/A
Jan 22, 2024	blackrock inc.	15.5%	4,989,247	SC 13G/A
Feb 09, 2023	wasatch advisors inc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	11.95%	3,841,468	SC 13G/A
Jan 26, 2023	blackrock inc.	15.5%	4,972,536	SC 13G/A
Jan 20, 2023	blackrock inc.	15.5%	4,972,536	SC 13G/A
Jan 12, 2023	apg asset management us inc.	8.5%	2,719,969	SC 13G/A
Feb 11, 2022	wasatch advisors inc	-	0	SC 13G

Recent SEC filings of Balchem Corp

View All Filings

Date Filed	Form Type	Document
Mar 29, 2024	8-K	Current Report
Mar 12, 2024	4	Insider Trading
Mar 08, 2024	144	Notice of Insider Sale Intent
Mar 06, 2024	4	Insider Trading
Mar 04, 2024	144	Notice of Insider Sale Intent
Feb 27, 2024	4	Insider Trading
Feb 26, 2024	144	Notice of Insider Sale Intent
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading

Peers (Alternatives to Balchem Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
APD	52.2B	12.4B	-1.27%	-20.32%	22.34	4.2	-3.54%	3.06%
DOW	40.2B	44.6B	-1.61%	2.46%	60.93	0.9	-21.58%	-85.78%
AVTR	17.2B	7.0B	-1.61%	27.30%	53.65	2.47	-7.26%	-53.23%
CE	16.9B	10.9B	-5.63%	47.70%	8.64	1.55	13.10%	3.48%
ALB	13.5B	9.6B	-5.52%	-37.93%	8.6	1.41	31.38%	-41.50%
EMN	11.3B	9.2B	1.63%	17.76%	12.65	1.23	-12.95%	12.74%
MID-CAP
CBT	5.2B	3.9B	3.43%	24.94%	11.64	1.32	-9.12%	26.64%
BCPC	4.7B	922.4M	-6.77%	12.46%	43.13	5.07	-2.11%	3.01%
AVNT	3.9B	3.1B	4.71%	9.92%	51.93	1.26	-7.48%	-89.19%
ARCH	2.9B	3.1B	-3.66%	24.21%	6.23	0.91	-15.54%	-65.21%
SMALL-CAP
CCF	1.2B	404.0M	0.11%	32.60%	36.59	3	24.06%	-25.72%
ASIX	725.4M	1.5B	1.53%	-30.74%	13.28	0.47	-21.18%	-60.55%
CMT	176.9M	357.7M	5.18%	0.56%	8.71	0.49	-5.20%	66.55%
AREC	105.7M	16.7M	-6.76%	14.05%	9.54	6.31	-57.58%	866.09%
AMRS	3.7M	-	-80.00%	-99.58%	-0.01	0.01	-	-

Balchem Corp News

Latest updates

Balchem Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-0.5%	229	230	231	233	233	244	237	229	213	198	202	186	181	175	173	174	167	159	162	157	164
Cost Of Revenue	0.2%	154	153	154	159	164	176	165	157	149	137	143	127	124	119	118	119	112	105	108	108	112
Gross Profit	-2.0%	75.00	77.00	77.00	73.00	69.00	68.00	72.00	72.00	64.00	61.00	59.00	59.00	57.00	56.00	55.00	55.00	54.00	54.00	54.00	49.00	51.00
Operating Expenses	11.3%	37.00	33.00	35.00	39.00	35.00	35.00	32.00	33.00	30.00	28.00	29.00	28.00	28.00	27.00	28.00	29.00	31.00	28.00	28.00	23.00	24.00
S&GA Expenses	5.6%	19.00	18.00	19.00	18.00	18.00	17.00	16.00	17.00	15.00	15.00	15.00	15.00	15.00	14.00	14.00	15.00	16.00	15.00	15.00	14.00	14.00
R&D Expenses	1.8%	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	5.00	3.00	3.00	3.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
EBITDA Margin	5.1%	0.18*	0.17*	0.17*	0.17*	0.19*	0.20*	0.21*	0.21*	0.21*	0.22*	0.22*	0.22*	-	-	-	-	-	-	-	-	-
Interest Expenses	19.8%	-5.29	-6.59	-5.16	-5.56	-5.12	-3.64	-0.96	-0.55	-0.57	-0.56	-0.61	-0.72	-0.83	-0.95	-0.96	-1.70	-1.21	-1.67	-1.49	-1.59	-1.67
Income Taxes	-10.6%	7.00	7.00	8.00	6.00	4.00	6.00	9.00	9.00	8.00	7.00	7.00	7.00	6.00	6.00	5.00	5.00	2.00	4.00	5.00	6.00	5.00
Earnings Before Taxes	-8.8%	33.00	36.00	38.00	29.00	26.00	31.00	39.00	38.00	33.00	32.00	30.00	30.00	28.00	28.00	26.00	24.00	22.00	24.00	25.00	25.00	25.00
EBT Margin	6.2%	0.15*	0.14*	0.13*	0.13*	0.14*	0.15*	0.16*	0.16*	0.16*	0.16*	0.16*	0.16*	-	-	-	-	-	-	-	-	-
Net Income	-8.3%	27.00	29.00	30.00	23.00	21.00	25.00	30.00	29.00	25.00	25.00	23.00	23.00	22.00	22.00	21.00	20.00	20.00	21.00	20.00	19.00	20.00
Net Income Margin	5.5%	0.12*	0.11*	0.11*	0.10*	0.11*	0.12*	0.12*	0.12*	0.12*	0.12*	0.12*	0.12*	-	-	-	-	-	-	-	-	-
Free Cashflow	44.9%	67.00	47.00	29.00	29.00	35.00	35.00	42.00	1.00	38.00	33.00	30.00	34.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-0.4%	1,597	1,603	1,619	1,629	1,625	1,633	1,607	1,195	1,199	1,179	1,174	1,169	1,166	1,161	1,151	1,162	1,156	1,097	1,098	972	981
Current Assets	-7.9%	314	341	337	336	336	368	377	320	322	300	287	281	267	270	264	271	255	240	232	222	226
Cash Equivalents	-16.3%	64.00	77.00	67.00	60.00	67.00	56.00	76.00	64.00	103	90.00	80.00	89.00	85.00	79.00	76.00	74.00	66.00	59.00	42.00	39.00	54.00
Inventory	-5.9%	110	116	125	125	120	139	141	108	91.00	82.00	78.00	77.00	71.00	77.00	82.00	83.00	84.00	74.00	68.00	67.00	67.00
Net PPE	2.7%	276	269	271	276	271	260	252	240	238	230	228	227	228	220	217	215	217	201	204	188	191
Goodwill	1.6%	779	767	774	774	770	749	216	523	524	525	527	526	529	526	523	523	524	504	507	446	448
Liabilities	-6.1%	543	578	612	655	686	737	705	321	322	290	304	320	338	342	359	396	412	363	366	261	290
Current Liabilities	37.4%	148	108	114	117	140	142	144	124	144	105	101	89.00	94.00	68.00	68.00	72.00	92.00	72.00	62.00	64.00	82.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	156
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	156
Shareholder's Equity	2.8%	1,054	1,025	1,007	973	938	896	901	874	877	889	870	849	828	819	793	766	744	734	732	711	692
Retained Earnings	0.1%	897	896	867	837	814	816	791	761	732	728	703	680	657	653	632	611	591	587	567	547	528
Additional Paid-In Capital	3.3%	146	141	137	132	129	125	121	117	148	173	173	171	165	175	174	174	174	174	170	167	165
Shares Outstanding	0.0%	32.00	32.00	32.00	32.00	32.00	32.00	32.00	32.00	32.00	32.00	32.00	32.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	4,321	-	-	-	4,133	-	-	-	4,224	-	-	-	3,046	-	-	-	3,212	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	44.9%	67,406	46,526	34,991	34,838	41,655	41,620	48,240	7,021	44,491	39,634	35,782	40,607	47,954	35,360	44,615	22,565	32,967	42,682	26,329	22,483	39,512
Share Based Compensation	1.0%	3,785	3,749	3,748	4,770	3,386	2,949	3,812	3,077	1,993	2,895	3,292	2,622	1,548	2,254	2,320	2,181	1,879	2,095	1,991	1,631	1,205
Cashflow From Investing	-27.9%	-11,865	-9,276	-3,611	-10,061	-14,489	-85,113	-306,340	-10,072	-14,181	-7,599	-7,294	-6,226	-13,211	-7,787	-8,199	-5,394	-53,116	4,566	-101,895	-5,780	-5,642
Cashflow From Financing	-179.5%	-70,146	-25,098	-24,759	-33,318	-21,401	28,386	274,539	-34,845	-15,945	-20,506	-37,794	-27,933	-31,545	-26,692	-34,767	-8,160	25,760	-28,669	77,868	-31,574	-22,036
Dividend Payments	-100.0%	-	3.00	2.00	22,867	5.00	4.00	1.00	20,703	19.00	4.00	-	18,700	1.00	-	-	16,704	-	-	-	15,135	4.00
Buy Backs	339.6%	444	101	75.00	3,849	178	46.00	600	34,599	16,477	7,927	9,239	1,596	7,481	2,957	2,134	891	-	20,594	-	727	171

BCPC Income Statement

2023-12-31

Consolidated Statements of Earnings - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net sales	$ 922,439	$ 942,358	$ 799,023
Cost of sales	620,383	661,907	555,849
Gross margin	302,056	280,451	243,174
Operating expenses:
Selling expenses	74,397	67,409	60,413
Research and development expenses	15,049	12,191	13,524
General and administrative expenses	53,417	55,665	41,735
Total operating expenses	142,863	135,265	115,672
Earnings from operations	159,193	145,186	127,502
Other expenses:
Interest expense, net	22,613	10,268	2,456
Other (income) expense, net	(681)	1,169	(187)
Total other expenses	21,932	11,437	2,269
Earnings before income tax expense	137,261	133,749	125,233
Income tax expense	28,718	28,382	29,129
Net earnings	$ 108,543	$ 105,367	$ 96,104
Basic net earnings per common share (in dollars per share)	$ 3.38	$ 3.29	$ 2.98
Diluted net earnings per common share (in dollars per share)	$ 3.35	$ 3.25	$ 2.94

BCPC Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 64,447	$ 66,560
Accounts receivable, net of allowance for doubtful accounts of $908 and $1,226 at December 31, 2023 and 2022, respectively	125,284	131,578
Inventories, net	109,521	119,668
Prepaid expenses	7,798	4,903
Derivative assets	0	5,993
Other current assets	7,192	7,101
Total current assets	314,242	335,803
Property, plant and equipment, net	276,039	271,355
Goodwill	778,907	769,509
Intangible assets with finite lives, net	191,212	213,295
Right of use assets - operating leases	17,763	17,094
Right of use assets - finance lease	2,101	2,338
Other non-current assets	16,947	15,118
Total assets	1,597,211	1,624,512
Current liabilities:
Trade accounts payable	55,503	57,322
Accrued expenses	40,855	36,745
Accrued compensation and other benefits	17,228	16,544
Dividends payable	25,717	23,129
Income tax payable	4,967	2,280
Operating lease liabilities - current	3,949	3,796
Finance lease liabilities - current	272	226
Total current liabilities	148,491	140,042
Revolving loan	309,569	440,569
Deferred income taxes	52,046	62,784
Operating lease liabilities - non-current	14,601	13,806
Finance lease liabilities - non-current	1,943	2,213
Other long-term obligations	16,577	26,814
Total liabilities	543,227	686,228
Commitments and contingencies (Note 16)
Stockholders’ equity:
Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding	0	0
Common stock, $.0667 par value. Authorized 120,000,000 shares; 32,254,728 shares issued and outstanding at December 31, 2023 and 32,152,787 shares issued and outstanding at December 31, 2022, respectively	2,152	2,145
Additional paid-in capital	145,653	128,806
Retained earnings	897,488	814,487
Accumulated other comprehensive income (loss)	8,691	(7,154)
Total stockholders’ equity	1,053,984	938,284
Total liabilities and stockholders’ equity	$ 1,597,211	$ 1,624,512

About Balchem Corp

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment offers ethylene oxide primarily for use in the health care industry; single use canisters for sterilizing re-usable devices; and ammonia. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was incorporated in 1967 and is headquartered in Montvale, New Jersey.

CEO	Mr. Theodore L. Harris
WEBSITE	balchem.com
INDUSTRY	Chemicals
EMPLOYEES	1284

Balchem Corp Frequently Asked Questions

What is the ticker symbol for Balchem Corp? What does BCPC stand for in stocks?

BCPC is the stock ticker symbol of Balchem Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Balchem Corp (BCPC)?

As of Tue Apr 23 2024, market cap of Balchem Corp is 4.68 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BCPC stock?

You can check BCPC's fair value in chart for subscribers.

What is the fair value of BCPC stock?

You can check BCPC's fair value in chart for subscribers. The fair value of Balchem Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Balchem Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BCPC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Balchem Corp a good stock to buy?

The fair value guage provides a quick view whether BCPC is over valued or under valued. Whether Balchem Corp is cheap or expensive depends on the assumptions which impact Balchem Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCPC.

What is Balchem Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, BCPC's PE ratio (Price to Earnings) is 43.13 and Price to Sales (PS) ratio is 5.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BCPC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Balchem Corp's stock?

In the past 10 years, Balchem Corp has provided 0.093 (multiply by 100 for percentage) rate of return.